Indian pharmaceutical market records 17.1% growth in September: Equirus Securities
Strongest monthly growth in three years; 2QFY27 growth reaches 14.7 per cent
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Dr Reddy’s
Dr. Reddy’s expands collaboration with Gilead Sciences for investigational once-yearly…
Dr. Reddy's Laboratories announced a royalty-free non-exclusive voluntary licensing agreement with Gilead Sciences for…
Dr. Reddy’s Laboratories launches oral semaglutide biosimilar ‘Obeda’ tablets in India
Dr. Reddy’s Laboratories, a global pharmaceutical company, announced the launch of its oral semaglutide biosimilar, indicated for…
Dr. Reddy’s launches Hevaxin, a novel recombinant Hepatitis E vaccine in India
Dr. Reddy’s Laboratories announced the launch of Hevaxin, a novel recombinant vaccine for the prevention of Hepatitis E virus…
Dr. Reddy’s sets SBTi-approved Net Zero target for FY2045
The company outlines near-term and long-term emission reduction goals across its value chain
Dr. Reddy’s receives positive CHMP opinion from EMA for AVT03
Dr. Reddy’s Laboratories announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use…
Dr. Reddy’s launches Tegoprazan in India
Dr. Reddy’s Laboratories announced the launch of the novel molecule ‘Tegoprazan’, for acid-related gastrointestinal diseases in…
Dr. Reddy’s acquires STUGERON to strengthen its CNS portfolio
Dr. Reddy’s, a global pharmaceutical company has announced the completion of a definitive transaction with Johnson & Johnson,…
Gilead Sciences signs licencing agreements with six companies to manufacture, commercialise…
Dr Reddy’s Laboratories, Emcure Pharma, Hetero Drugs and Mylan Labs (a subsidiary of Viatris), are among the six companies that…
Dr Reddy’s receives positive CHMP opinion for biosimilar Rituximab candidate in European markets
Dr Reddy's Rituximab biosimilar DRL_RI (ITUXREDI) progresses towards European approval with EMA CHMP endorsement